Emergent Product Development UK Limited

Microscience Limited

Imperial College of Science, Technology and Medicine

Genome Research Limited

Medeva Holdings Bv

Rutgers, the State University of New Jersey

Acambis Research Limited

Celltech Pharma Europe Limited

Gordon Dougan

Robert Graham Feldman

Joseph David Santangelo

Paul Howard Everest

Richard James Dobson

Martin John Glenton Hughes

Joanne Christine Moore

Jonathan Douglas Lane

Rebecca Kerry Wilson

David William Holden

Jacqueline Elizabeth Shea

Steven Neville Chatfield

Zoe Hindle

Trevor D Lawley

Carlos Estenio Hormaeche

Mohammed Anjam Khan

Gad Frankel

Simon Clare

Pal Maliga

Mark Roberts

Enda Elizabeth Clarke

John Tregoning

Peter Nixon

Mark Sydenham

Helen Rachel Crooke

Bernardo Villarreal-Ramos

Caroline Joanne Henwood

A method, for the identification of bacterial isolates suitable for use in bacteriotherapy, the method comprising: (i) preparing a suspension of material collected from a host harbouring microbiota; (ii) addition of an activator of bacterial spores sufficient to allow growth of bacteria from spores present in the suspension; (iii) culturing the suspension; and (iv) identification of at least one bacterial species within the culture.

Method for the identification of bacteria

A method, for the identification of bacterial isolates suitable for use in bacteriotherapy, the method comprising: (i) preparing a suspension of material collected from a host harboring microbiota; (ii) addition of an activator of bacterial spores sufficient to allow growth of bacteria from spores present in the suspension; (iii) culturing the suspension; and (iv) identification of at least one bacterial species within the culture.

Method for identifying bacteria for bacteriotherapy

The present invention pertains to amicroorganism having an attenuating mutation which disrupts the expression of a gene located within the Spi2 pathogenicity island, and an auxotrophic mutation. The microorganism therefore has a double mutation which helps prevent reactivity of the microorganism while maintaining the effectiveness of the microorganism to elicit an immune response. The present invention also pertains to vaccine compositions and methods for treating and preventing ainfection in a patient.

Attenuated microorganisms for the treatment of infection

A protein from Group Bis shown to be an outer surface protein and is a useful target for antimicrobial therapy.

Genes and proteins, and their use

According to the present invention, a series of genes are identified in Group B Streptococcus, the products of which may be associated with the outer surface of the organism. The genes, or functional fragments thereof, may be useful in the preparation of therapeutics, e.g. vaccines to immunize a patient against microbial infection.

According to the present invention, a series of genes are identified in Group B, the products of which may be located on the outer surface of the organism. The genes, or functional fragments thereof, may be useful in the preparation of therapeutics, e.g. vaccines for the immunization of a patient against microbial infection.

NADP-dependent glyceraldehyde-3-phosphate dehydrogenase for therapeutic use

A site specific recombination system and methods of use thereof are disclosed for manipulating the genome of higher plants. Compositions and methods for expressing immunogenic proteins using the site specific reombination system are also provided.

High level expression of immunogenic proteins in the plastids of higher plants

The invention relates to a vaccine comprising a bacterium attenuated by a non-reverting mutation in a gene encoding a protein which promotes folding of extracytoplasmic proteins. Such mutations were initially identified as being useful in vaccines from a bank of randomly inserted, transposon mutants in which attenuation was determined as a reduction in virulence of the organism in the mouse model of infection. Site directed mutation of the gene results in a strain which shows at least 4 logs of attenuation when delivered both orally and intravenously. Animals vaccinated with such a strain are protected against subsequent challenge with the parent wild type strain. Finally, heterologous antigens such as the non-toxic and protective, binding domain from tetanus toxin, fragment C, can be delivered via the mucosal immune system using such strains of bacteria. This results in the induction of a fully protective immune response to subsequent challenge with native tetanus toxin.

Vaccines containing attenuated bacteria

The present invention is based on the identification of a series of virulence genes inK1, the products of which may be implicated in the pathogenicity of the organisms. The identification of the genes allows them, or their expressed products, to be used in a number of ways to treat infection.

Virulence genes and proteins, and their use

According to the present invention, a series of genes are identified in Group B Streptococcus, the products of which may be associated with the outer surface of the organism. The genes, or functional fragments thereof, may be useful in the preparation of therapeutics, e.g. vacaccines to immunize a patient against microbial infection.

Genes and proteins and their use

The present invention pertains to a Salmonella microorganism having an attenuating mutation which disrupts the expression of a gene located within the Spi2 pathogenicity island, and an auxotrophic mutation. The microorganism therefore has a double mutation which helps prevent reactivity of the microorganism while maintaining the effectiveness of the microorganism to elicit an immune response. The present invention also pertains to vaccine compositions and methods for treating and preventing a Salmonella infection in a patient.

The invention provides a DNA molecule comprising a promoter sequence operably linked to a DNA sequence encoding first and second proteins linked by a hinge region wherein in that the promoter sequence can be one having activity which is induced in response to a change in the surrounding environment and the first protein can be Tetanus toxin C fragment or one or more epitopes thereof. The invention also provides intermediate molecules having a promoter operably linked to a DNA sequence encoding a first antigenic sequence and a hinge region, and at or adjacent the 3&prime;-end thereof one or more restriction sites for the introduction of a second anti-genic sequence. In addition, the invention provides replicable expression vectors containing the DNA fusion proteins expressed therefrom, bacterial transformed with the vectors and the use of the bacteria, in vaccines.

Expression of recombinant fusion proteins in attenuated bacteria

The invention is related to antibodies, particularly monoclonal antibodies, which recognize particularly epitopes of the intimin protein of enteropathogenic and enterohemorrhagic , methods of detecting such by use of these antibodies, and kits containing these antibodies for diagnosis.

Growing community of inventors

London, United Kingdom

Gordon Dougan